SAMHD1 Antibody

• Catalog Number: orb1239948
• Category: Antibodies
• Description: SAMHD1 Antibody
• Target: SAMHD1
• Clonality: Polyclonal
• Isotype: IgG
• Conjugation: Unconjugated
• Reactivity: Human, Mouse
• Form/Appearance: Liquid
• Concentration: 1 mg/mL
• Buffer/Preservatives: SAMHD1 antibody is supplied in PBS containing 0.02% sodium azide.
• Purification: SAMHD1 antibody is affinity chromatography purified via peptide column.
• Immunogen: Anti-SAMHD1 antibody (orb1239948) was raised against a peptide corresponding to 18 amino acids near the carboxy terminus of human SAMHD1.
• UniProt ID: Q9Y3Z3
• MW: Predicted: 72kDObserved: 72 kD
• Tested applications: ELISA, IF, IHC, WB
• Antibody Type: Primary Antibody
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Alternative names: SAM domain and HD domain 1, DCIP, CHBL2, HDDC1, MO
• Research Area: Immunology & Inflammation
• Note: For research use only
• NCBI: NP_056289

Western Blot Validation in Human Daudi Cell Lines. Loading: 15 µg of lysates per lane. Antibodies: SAMHD1 orb1239948, 1 µg/mL, in (A: the absence and B: the presence of blocking peptide), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Overexpression Validation in 293T Transfected Cells. Loading: 15 µg of lysates per lane. Antibodies: SAMHD1 orb1239948 (0.1 µg/mL), (1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. 293 cells were transfected with (1) wild-type SAMHD1 or (2) SAMHD1 (mutation T592A).

Immunohistochemistry Validation of SAMHD1 in Human Brain Tissue. Immunohistochemical analysis of paraffin-embedded Human Brain Tissue using anti-SAMHD1 antibody (orb1239948) at 5 µg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 °C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Immunofluorescence Validation of SAMHD1 in Human Daudi cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed Human Daudi Cells labeling SAMHD1 with orb1239948 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

KO Validation of SAMHD1 in xenograft mice (Kodigepalli et al., 2018). THP-1 control and SAMHD1 KO (THP-1/KO) cells were injected into NSG (non-obese diabetic/severe combinedimmune deficient-gamma) mice. Protein expression levels of SAMHD1 were examined by Western blot with anti-SAMHD1 antibodies (orb1239948) and SAMHD1 was not detected in THP-1/KO cells.

Overexpression Validation of SAMHD1 in CD4+ T-cells from a healthy donor and transformed CD4+ T-cell lines (Kohnken et al., 2017). MT1, MT2, SLB-1, and C8166 were from leukemia patients and HH, HuT78, and HuT102 were from cutaneous T-cell lymphoma (CTCL) patients. SAMHD1 protein expression detected by anti-SAMHD1 antibodies (orb1239948) was significantly increased in normal CD4+ T-cells as compared to leukemia- and CTCL- derived CD4+ T-cell lines. This blot is representative from four independent experiments with four healthy donors.

Overexpression of SAMHD1 in CD4+ T-cells from Healthy Donors and Sézary Syndrome (SS) patients (Kohnken et al., 2017). SAMHD1 protein expression detected by anti-SAMHD1 antibodies (orb1239948) was significantly reduced in CD+ T-cells from 15 SS patients as compared to those from 7 healthy donors.

Regulated Expression Validation of SAMHD1 in CD4+ T-cells from a healthy donor (Kohnken et al., 2017). SAMHD1 protein expression detected by anti-SAMHD1 antibodies (orb1239948) was significantly decreased by about 40% relative to control cells at 48hr post-nucleofection with miR-181b.

Regulated Expression Validation of SAMHD1 in MT2 CD4+ T-cells from leukemia patients (Kohnken et al., 2017). SAMHD1 protein expression detected by anti-SAMHD1 antibodies (orb1239948) was significantly increased by 5-fold at 48hr post-nucleofection with miR-181family inhibitor treatment.